By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immunovaccine Inc. 

1819 Granville Street
Suite 303
Halifax  Nova Scotia  B3J 3R1  Canada
Phone: 902-492-1819 Fax: 902-492-0888




Company News
Immunovaccine Inc. Announces Financial Results For Quarter Ended September 30, 2015 11/13/2015 1:01:37 PM
Immunovaccine Inc.'s Vaccine Candidate For Respiratory Syncytial Virus Is Well Tolerated In Volunteers In Phase 1 Clinical Trial 10/30/2015 12:42:19 PM
Immunovaccine Inc. Announces Financial Results For Quarter Ended June 30, 2015 8/13/2015 9:27:22 AM
Immunovaccine Inc. And PharmAthene, Inc. (PIP) Sign Exclusive Worldwide License Agreement To Develop And Commercialize An Anthrax Vaccine Formulated In DepoVax 7/8/2015 10:52:03 AM
Immunovaccine Inc. Initiates Clinical Trial With DPX-RSV Vaccine 7/2/2015 1:21:09 PM
Immunovaccine Inc. Publishes Clinical Results With DPX-Survivac In Combination With An Immune-Modulating Compound 7/2/2015 1:15:27 PM
Ebola Epidemic Unlikely But Not Impossible, Says Immunovaccine Inc. CEO 10/29/2014 8:02:06 AM
Immunovaccine Inc. Demonstrates Protection Against Lethal Anthrax Challenge With Rapid Acting, Single Dose Vaccine 10/21/2014 2:17:54 PM
Immunovaccine Inc. To Provide Update On Ongoing Ebola Virus And Cancer Vaccine Programs At 13th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/20/2014 2:59:00 PM
Ebola Vaccine Using Immunovaccine Inc.’s DepoVax Proves Highly Efficacious In Non-Human Primate Study 10/20/2014 1:25:46 PM